This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

National Survey Identifies Potential Barriers To HIV Treatment Use In U.S.

Stock quotes in this article: GSK, PFE

RESEARCH TRIANGLE PARK, N.C., June 10, 2014 /PRNewswire/ -- ViiV Healthcare today announced new survey data that provide important insights that may help explain why HIV treatment rates remain low in the United States. Findings from the online survey, conducted by Harris Interactive on behalf of ViiV Healthcare in 2013, reveal gaps in knowledge about HIV and its treatment among diagnosed but untreated people living with HIV (PLWHIV), as well as misperceptions about HIV prescription medicine and fewer positive perceptions of overall well-being compared to those of PLWHIV who are treating their disease.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/7206151-viiv-healthcare-hiv-patient-survey

National Survey Identifies Potential Barriers to HIV Treatment Use in U.S.

Both the U.S. Centers for Disease Control and Prevention and the Department of Health and Human Services recommend early treatment for the benefit of the HIV patient.[i] Still, many PLWHIV do not initiate therapy at the time of diagnosis, if at all. In fact, despite significant strides in HIV therapy and access, only 33 percent of the 1.1 million Americans living with HIV are taking the medicines they need to live longer, healthier lives and reduce the chance of passing the disease on to a partner.[ii]

"There is mounting evidence clearly establishing many personal and public health benefits that go along with HIV treatment. Earlier treatment and a suppressed viral load help reduce the number of new infections and slow the virus' ability to damage the body.[iii] But this survey shows that gaps in knowledge about treatment among people living with HIV may serve as potential barriers to antiretroviral therapy," said Julie Scofield, Executive Director, National Alliance of State & Territorial AIDS Directors. "Educating people about the importance and benefits of HIV treatment is critical, as is improving linkages to and retaining people in care – particularly in communities of color, where later-stage AIDS diagnoses are more common than earlier-stage HIV diagnoses."

The survey findings point to the following four potential barriers to treatment use by comparing the reported perceptions and experiences of HIV-positive adults (aged 18+) who had never taken a prescription medicine to treat their HIV ("untreated patients") to those who had begun taking a prescription medicine to treat their HIV in the past five years ("treated patients"):

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,766.43 -38.28 -0.23%
S&P 500 1,937.81 -8.35 -0.43%
NASDAQ 4,407.2870 -14.7980 -0.33%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs